Lewy Body Dementia (LBD) Market to Reach USD 5.12 Billion by 2034

Pune, India - December 2025 - The global Lewy Body Dementia (LBD) Market, valued at USD 2.98 billion in 2024, is projected to reach USD 5.12 billion by 2034, growing at a 5.6% CAGR (2025-2034), according to Exactitude Consultancy. Rising neurodegenerative disease prevalence, improved diagnostic imaging, and growing awareness of cognitive and behavioral symptoms are driving market expansion.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71909

Market Summary
The Lewy Body Dementia Market is expanding as LBD-characterized by abnormal deposition of alpha-synuclein (Lewy bodies) in neurons-becomes increasingly recognized as the second most common degenerative dementia after Alzheimer's disease. The condition includes Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD).

Diagnosis has improved with advances in MRI, DaTscan (dopamine transporter imaging), neuropsychological testing, and emerging blood- and CSF-based biomarkers. Key clinical features include fluctuating cognition, visual hallucinations, REM sleep behavior disorder (RBD), parkinsonism, and autonomic dysfunction.

Treatment focuses on managing symptoms, as LBD currently has no cure. Commonly used therapies include:
• Cholinesterase inhibitors (rivastigmine, donepezil) for cognitive impairment
• Levodopa for parkinsonian symptoms
• Melatonin and clonazepam for RBD
• Atypical antipsychotics (with caution due to severe sensitivity risks)
Growing R&D in alpha-synuclein-targeted therapies, neuroprotective agents, and precision diagnostics is shaping future innovation.
North America and Europe dominate due to high diagnosis rates and advanced care pathways, while Asia-Pacific is the fastest-growing region, driven by aging populations and increasing neurodegenerative disease burden.

Key Takeaways
• 2024 Market Size: USD 2.98 Billion
• 2034 Forecast: USD 5.12 Billion
• CAGR: 5.6% (2025-2034)**
• Significant growth expected in behavioral and cognitive symptom management
• Improved neuroimaging is expanding accurate diagnosis of LBD
• Asia-Pacific emerging as a major patient pool due to rapid aging

Market Drivers
• Rising global prevalence of dementia and Parkinsonian disorders
• Growing awareness and improved screening for LBD symptoms
• Expansion of neuroimaging technologies and biomarker diagnostics
• Increasing burden of age-related neurodegenerative conditions
• Advancements in alpha-synuclein-focused therapeutic research

Segmentation Snapshot
By Disease Type
• Dementia with Lewy Bodies (DLB) - Largest Segment
• Parkinson's Disease Dementia (PDD)

By Treatment Type
• Cholinesterase Inhibitors (Rivastigmine, Donepezil)
• Levodopa & Dopaminergic Medications
• Antipsychotics (With Caution)
• Melatonin & Clonazepam for RBD
• Supportive & Behavioral Therapies
• Pipeline Therapies (Synuclein-targeted, Neuroprotective Agents)

By Diagnosis
• Cognitive Assessment
• Neurological Examination
• MRI & CT Imaging
• DaTscan / PET Imaging
• CSF Biomarker Panels
• Blood-based Biomarker Testing (Emerging)

By End User
• Hospitals
• Neurology Clinics
• Memory Care Centers
• Diagnostic Laboratories
• Research Institutions

By Region
• North America (Largest Market)
• Europe
• Asia-Pacific (Fastest Growing)
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/71909/lewy-body-dementia-market

Recent Developments
• Increased adoption of DaTscan imaging for accurate differentiation of LBD from Alzheimer's disease.
• Advancements in CSF and blood biomarkers enabling earlier diagnosis.
• Clinical trials targeting alpha-synuclein aggregation showing early promise.
• Digital cognitive assessment tools aiding remote diagnosis and monitoring.

Expert Quote - Irfan Tamboli, Business Development Executive
"Lewy Body Dementia is gaining long-overdue clinical recognition. As imaging, biomarkers, and cognitive assessment tools advance, diagnosis is improving and opening the way for more targeted therapeutic research."

Conclusion
The Lewy Body Dementia Market will continue strengthening through 2034 as global aging accelerates, diagnostic pathways expand, and innovation in neurodegeneration therapeutics progresses. Companies focusing on synuclein-targeted drugs, biomarker-driven diagnostics, cognitive technologies, and integrated dementia care models will lead the next decade of market growth.

This report is also available in the following languages : Japanese (レビー小体型認知症市場), Korean (루이소체 치매 시장), Chinese (路易体痴呆症市场), French (Marché de la démence à corps de Lewy), German (Markt für Lewy-Körper-Demenz), and Italian (Mercato della demenza da corpi di Lewy), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71909

Related Reports

Dementia Market
https://exactitudeconsultancy.com/reports/71932/dementia-market

Dementia with Lewy Bodies Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72099/dementia-with-lewy-bodies-patient-pool-analysis-market

Dementia Clinical Market
https://exactitudeconsultancy.com/reports/73654/dementia-clinical-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.